REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

20/03/2020 08:12

RNS Number : 8802G
  
AstraZeneca PLC
  
20 March 2020
  
 

20 March 2020 07:00 GMT
 
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announced that, on 19 March 2020, it was notified by Tony Mok, a Non-Executive Director of the Company, that, on 18 March 2020, Mr Mok purchased 1,000 of the Company's American Depositary Shares (ADSs) at a price of $38.32 per ADS. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.
 
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
 



1 
 


Details of the person discharging managerial responsibilities / person closely associated 
 




a) 
 


Name 
 
 


Tony Mok




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 
 


Non-Executive Director




b) 
 


Initial notification /Amendment 
 
 


Initial notification




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
 




a) 
 


Name 
 
 


AstraZeneca PLC




b) 
 


LEI 
 
 


PY6ZZQWO2IZFZC3IOL08




4 
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
 
 




a) 
 


Description of the financial instrument, type of instrument 
 
Identification code 
 
 


AstraZeneca PLC American Depositary Shares
 
 
CUSIP: 046353108




b) 
 


Nature of the transaction 
 
 


Purchase of AstraZeneca PLC American Depositary Shares




c) 
 


Price(s) and volume(s) 
 
 


 



Price(s)
 


Volume(s)




US$38.32


1,000



 
 




d) 
 


Aggregated information 
 
 
- Aggregated volume 
 
 
- Price 
 
 


Not applicable - single transaction
 




e) 
 


Date of the transaction 
 
 


18 March 2020




f) 
 


Place of the transaction 
 
 


NYSE



 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.



Media Relations












Gonzalo Viña 






+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Angela Fiorin


BioPharmaceuticals


+44 1223 344 690




Jennifer Hursit


Other 


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals 
(Cardiovascular, Metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (Renal) Environmental, Social and Governance


+44 203 749 5716




Josie Afolabi


BioPharmaceuticals (Respiratory)
 


+44 203 749 5631




Tom Waldron


Other medicines


+44 7385 033 717




Craig Marks


Finance
Fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access
Retail investors


+44 203 749 5824




US toll-free






+1 866 381 72 77





Adrian Kemp

Company Secretary

AstraZeneca PLC
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHUKRBRRKUOAAR